Goldman Sachs’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-5,400
| Closed | -$442K | – | 6628 |
|
|
2021
Q3 | $442K | Hold |
5,400
| – | – | ﹤0.01% | 5266 |
|
|
2021
Q2 | $493K | Hold |
5,400
| – | – | ﹤0.01% | 5235 |
|
|
2021
Q1 | $462K | Buy |
+5,400
| New | +$485K | ﹤0.01% | 5180 |
|
|
2020
Q4 | – | Sell |
-50,000
| Closed | -$4.35M | – | 5633 |
|
|
2020
Q3 | $4.35M | Sell |
50,000
-116,100
| -70% | -$10.1M | ﹤0.01% | 3020 |
|
|
2020
Q2 | $14.5M | Sell |
166,100
-19,600
| -11% | -$1.69M | ﹤0.01% | 1949 |
|
|
2020
Q1 | $15.3M | Buy |
185,700
+27,600
| +17% | +$2.46M | 0.01% | 1724 |
|
|
2019
Q4 | $15M | Buy |
158,100
+2,500
| +2% | +$224K | ﹤0.01% | 2104 |
|
|
2019
Q3 | $13.5M | Sell |
155,600
-336,400
| -68% | -$30.2M | ﹤0.01% | 2116 |
|
|
2019
Q2 | $44.9M | Buy |
492,000
+478,608
| +3,574% | +$40.5M | 0.01% | 1209 |
|
|
2019
Q1 | $1.15M | Buy |
+13,392
| New | +$1.08M | ﹤0.01% | 3973 |
|
|
2018
Q4 | – | Sell |
-4,352
| Closed | -$336K | – | 5538 |
|
|
2018
Q3 | $336K | Buy |
4,352
+4,240
| +3,786% | +$313K | ﹤0.01% | 4653 |
|
|
2018
Q2 | $8K | Sell |
112
-223
| -67% | -$15.4K | ﹤0.01% | 5558 |
|
|
2018
Q1 | $24K | Sell |
335
-9,039
| -96% | -$688K | ﹤0.01% | 5637 |
|
|
2017
Q4 | $705K | Sell |
9,374
-4,911
| -34% | -$371K | ﹤0.01% | 4564 |
|
|
2017
Q3 | $1.1M | Buy |
14,285
+10,491
| +277% | +$792K | ﹤0.01% | 4496 |
|
|
2017
Q2 | $284K | Sell |
3,794
-3,348
| -47% | -$237K | ﹤0.01% | 5552 |
|
|
2017
Q1 | $475K | Sell |
7,142
-1,018,574
| -99% | -$67.9M | ﹤0.01% | 5080 |
|
|
2016
Q4 | $66.9M | Buy |
1,025,716
+968,800
| +1,702% | +$62.8M | 0.02% | 1058 |
|
|
2016
Q3 | $4.03M | Buy |
56,916
+50,555
| +795% | +$3.68M | ﹤0.01% | 3231 |
|
|
2016
Q2 | $470K | Buy |
6,361
+2,790
| +78% | +$193K | ﹤0.01% | 4902 |
|
|
2016
Q1 | $232K | Sell |
3,571
-8,370
| -70% | -$569K | ﹤0.01% | 5488 |
|
|
2015
Q4 | $921K | Sell |
11,941
-11,272
| -49% | -$895K | ﹤0.01% | 4384 |
|
|
2015
Q3 | $1.91M | Sell |
23,213
-2,678
| -10% | -$238K | ﹤0.01% | 3843 |
|
|
2015
Q2 | $2.28M | Buy |
25,891
+11,829
| +84% | +$1.09M | ﹤0.01% | 3711 |
|
|
2015
Q1 | $1.24M | Sell |
14,062
-26,784
| -66% | -$2.38M | ﹤0.01% | 4255 |
|
|
2014
Q4 | $3.39M | Sell |
40,846
-105,350
| -72% | -$8.73M | ﹤0.01% | 3346 |
|
|
2014
Q3 | $12.3M | Sell |
146,196
-14,285
| -9% | -$1.16M | ﹤0.01% | 2197 |
|
|
2014
Q2 | $13M | Sell |
160,481
-8,928
| -5% | -$702K | ﹤0.01% | 2151 |
|
|
2014
Q1 | $12.9M | Sell |
169,409
-164,163
| -49% | -$12M | ﹤0.01% | 2138 |
|
|
2013
Q4 | $24M | Buy |
333,572
+129,456
| +63% | +$9M | 0.01% | 1600 |
|
|
2013
Q3 | $14M | Buy |
204,116
+145,972
| +251% | +$9.66M | 0.01% | 1916 |
|
|
2013
Q2 | $3.68M | Buy |
+58,144
| New | +$3.78M | ﹤0.01% | 3055 |
|
Other funds holding NVS
Goldman Sachs's NVS Position: Q1 2026 in Review
Goldman Sachs increased its Novartis (NVS) stake by 138% in Q1 2026, buying an estimated $579M and bringing the position to 6,525,771 shares worth $997M. The position accounts for 0.11% of the portfolio, ranked #170.
Goldman Sachs first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Goldman Sachs held 6,525,771 shares of Novartis worth $997M as of Q1 2026.
- Goldman Sachs bought 3,780,327 Novartis shares in Q1 2026, an estimated $579M.
- Novartis made up 0.11% of Goldman Sachs's portfolio in Q1 2026, its #170 holding.
- Goldman Sachs first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
- 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.